Tag: Olivier Litzka
Biotech has to adjust to a dry spell in terms of financing
DNA experiment In view of the declining inflow of capital, rapid successes are required in research. (Photo: imago images/Westend61) Frankfurt The collapse of the Silicon Valley Bank (SVB) and the…
Biotech companies will raise less capital in 2022
Frankfurt After record figures in the first two years of the corona pandemic, German biotech companies raised significantly less capital in 2022. A total of 921 million euros in fresh…
Tomorrow’s biontech: venture capitalists reveal Germany’s biotech hopes
Frankfurt The success of the Covid-19 vaccine developer Biontech has brought new attention to German biotech companies. However, regardless of the success of Biontech, the industry has again moved more…